Crinetics Pharmaceuticals Equity 2024

Crinetics Pharmaceuticals Aktienanalyse

What does Crinetics Pharmaceuticals do?

Crinetics Pharmaceuticals Inc. is a leading biopharmaceutical company specializing in the development and commercialization of innovative therapies for rare endocrine diseases and hormone-dependent tumors. The company was founded in 2008 by a team of experienced pharmacy professionals and is headquartered in San Diego, California. History Crinetics Pharmaceuticals was founded based on groundbreaking research in the field of endocrine diseases. The company aims to develop innovative therapies for rare endocrine diseases and hormone-dependent tumors that have been inadequately treated thus far. Crinetics draws on decades of experience and in-depth knowledge in the fields of endocrinology, neuroscience, and cancer research. Business model Crinetics is a research and development company specializing in the discovery, development, and commercialization of drugs for rare endocrine diseases. The company has an extensive portfolio of proprietary compounds based on novel mechanisms of action that are in various stages of development. Crinetics works closely with leading experts in the field of endocrinology and oncology to develop and commercialize groundbreaking new therapies. Different divisions Crinetics specializes in the research, development, and commercialization of products that can be used in rare endocrine diseases and hormone-dependent tumors. The company operates in various areas, including: - Acromegaly: Crinetics is developing a medication for the treatment of acromegaly, a rare disease caused by overproduction of growth hormone. - Cushing's syndrome: Crinetics is developing a medication for the treatment of Cushing's syndrome, a rare disease caused by overproduction of cortisol. - Hypoparathyroidism: Crinetics is developing a medication for the treatment of hypoparathyroidism, a rare disease characterized by insufficient production of parathyroid hormone. - Neuroendocrine tumors: Crinetics is developing a medication for the treatment of neuroendocrine tumors, a rare group of tumors that arise from neuroendocrine cells. Products Crinetics has an extensive portfolio of innovative products based on novel mechanisms of action that are in various stages of development. The company focuses on developing drugs that can be used in rare endocrine diseases and hormone-dependent tumors. Some of the notable products are: - CRN00808: CRN00808 is a medication that can help improve the body's monitoring system that regulates the release of growth hormones. It is currently in phase 2 clinical trials. - CRN01941: CRN01941 is a medication for the treatment of Cushing's syndrome. It has been developed to inhibit excessive production of cortisol and is currently in phase 2 clinical trials. - CRN04777: CRN04777 is a medication for the treatment of acromegaly. It has been developed to inhibit overproduction of growth hormone and is currently in phase 1 clinical trials. - CRN04894: CRN04894 is a medication for the treatment of hypoparathyroidism. It has been developed to stimulate parathyroid hormone production and is currently in phase 1 clinical trials. Conclusion Crinetics Pharmaceuticals is a leading biopharmaceutical company specializing in the development of innovative therapies for rare endocrine diseases and hormone-dependent tumors. The company has an extensive portfolio of proprietary compounds based on novel mechanisms of action that are in various stages of development. Crinetics works closely with leading experts in the field of endocrinology and oncology to develop and commercialize groundbreaking new therapies. Crinetics Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Crinetics Pharmaceuticals's Equity

Crinetics Pharmaceuticals's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Crinetics Pharmaceuticals's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Crinetics Pharmaceuticals's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Crinetics Pharmaceuticals's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Crinetics Pharmaceuticals’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Crinetics Pharmaceuticals Stock

What is the equity of Crinetics Pharmaceuticals this year?

Crinetics Pharmaceuticals has equity of 539.11 M USD this year.

What was the equity of Crinetics Pharmaceuticals compared to the previous year?

The equity of Crinetics Pharmaceuticals has increased/decreased by 70.44% increased compared to the previous year.

What impact does a high equity have on investors of Crinetics Pharmaceuticals?

A high equity is advantageous for investors of Crinetics Pharmaceuticals as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Crinetics Pharmaceuticals?

A low equity can be a risk for investors of Crinetics Pharmaceuticals, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Crinetics Pharmaceuticals affect the company?

An increase in equity of Crinetics Pharmaceuticals can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Crinetics Pharmaceuticals affect the company?

A reduction in equity of Crinetics Pharmaceuticals can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Crinetics Pharmaceuticals?

Some factors that can affect the equity of Crinetics Pharmaceuticals include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Crinetics Pharmaceuticals so important for investors?

The equity of Crinetics Pharmaceuticals is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Crinetics Pharmaceuticals take to change the equity?

To change equity, Crinetics Pharmaceuticals can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Crinetics Pharmaceuticals pay?

Over the past 12 months, Crinetics Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Crinetics Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Crinetics Pharmaceuticals?

The current dividend yield of Crinetics Pharmaceuticals is .

When does Crinetics Pharmaceuticals pay dividends?

Crinetics Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Crinetics Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Crinetics Pharmaceuticals located?

Crinetics Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Crinetics Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Crinetics Pharmaceuticals from 6/20/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/20/2024.

When did Crinetics Pharmaceuticals pay the last dividend?

The last dividend was paid out on 6/20/2024.

What was the dividend of Crinetics Pharmaceuticals in the year 2023?

In the year 2023, Crinetics Pharmaceuticals distributed 0 USD as dividends.

In which currency does Crinetics Pharmaceuticals pay out the dividend?

The dividends of Crinetics Pharmaceuticals are distributed in USD.